On October 9, CSPC PHARMA fell 3.07% in regular trading, trading at 9.0 Hong Kong dollars, with Turnover of 2.75 billion Hong Kong dollars.

On the news front, the innovative drug sector faced broad pressure after the holiday, as Allist's core product furmonertinib missed its primary endpoint in a global Phase III trial, triggering market concerns over innovative drug pipeline delivery and dragging Hong Kong-listed pharmaceutical stocks generally lower. Despite CSPC PHARMA recently disclosing multiple R&D advances, including Phase I data for SYS6002 in cervical cancer, eight clinical updates to be presented at the ESMO annual meeting, and positive Phase III results for a GLP-1 diabetes asset, the stock retreated alongside the sector-wide adjustment.

Within the Pharmaceuticals sector, HENGRUI PHARMA fell 3.22%, HANSOH PHARMA fell 2.3%, SBP GROUP fell 1.73%, ASYMCHEM fell 6.99%, and HUTCHMED fell 1.48%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)